Thermo Fisher Scientific announced this week that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GSK for approximately $100 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex APIs. Thermo Fisher will continue to produce APIs for GSK under a multi-year supply agreement and plans to expand use of the site to develop and produce complex APIs for other customers as well. The site contains 270,000 liters of reactor capacity, 10 production buildings, an R&D pilot plant and lab infrastructure. Learn More